Senti Biosciences Holdings, Inc. 8-K

What Happened
Senti Biosciences Holdings, Inc. (SNTI) filed a Form 8-K on May 14, 2026 to announce its quarterly financial results for the quarter ended March 31, 2026. The company furnished press releases with the results as Exhibits 99.1 and 99.2 to the Form 8-K. The report was signed and dated May 14, 2026 by CEO Timothy Lu, M.D., Ph.D.

Key Details

• Event filed: Form 8-K (Items 2.02 and 8.01) on May 14, 2026.
• Period covered: Quarter ended March 31, 2026 (Q1 2026).
• Press releases: Furnished as Exhibit 99.1 and Exhibit 99.2 to the 8-K.
• Authorized signatory: Timothy Lu, Chief Executive Officer, executed the filing.

Why It Matters
This filing notifies investors that Senti has released its quarterly results; those press releases will contain the specific earnings, revenue, cash position, and any operational or clinical updates that could affect the stock. Retail investors should read the furnished press release exhibits for the detailed financial figures and commentary, since the 8-K itself only indicates that the results were announced and provides the press release as an exhibit.